Tag - SGMO

Executive Moves

Sangamo Therapeutics names Dr. Bettina Cockroft as SVP and CMO

Bettina Cockroft Sangamo Therapeutics (NASDAQ:SGMO) appointed Dr. Bettina Cockroft as SVP and CMO to oversee clinical development activities and operations. Sangamo is using its ex vivo gene-edited cell...

September 30, 2019

Markets

HCW starts Sangamo Therapeutics at buy; PT $16

H.C. Wainwright initiated coverage of Sangamo Therapeutics (NASDAQ:SGMO) with a “buy” rating and $16 price target. The stock closed at $11.02 on Aug. 23. Analyst Debjit Chattopadhyay writes that the prevailing view on...

August 26, 2019

Tag - SGMO

Sangamo Therapeutics names Dr. Bettina Cockroft as SVP and CMO

HCW starts Sangamo Therapeutics at buy; PT $16

General

More